Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Next Previous
Trial Profile

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Ductal carcinoma; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms AMPLIFY-7P
  • Sponsors Elicio Therapeutics

Most Recent Events

  • 31 Mar 2025 According to an Elicio Therapeutics media release, company look forward DFS event-driven interim analysis from this trial in Q3 2025, depending on rate of event accrual
  • 27 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 12 Dec 2024 According to an Elicio Therapeutics media release, company look forward to the interim analysis of the randomized Phase 2 portion of AMPLIFY-7P, expected in the first half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top